Advanced search
Publication Cover
Acta Oncologica Volume 45, 2006 - Issue 4
Journal homepage
1,202
Views
28
CrossRef citations to date
0
Altmetric
ORIGINAL ARTICLE

Long-term survival benefit after adjuvant treatment of cutaneous melanoma with dacarbazine and low dose natural interferon alpha: A controlled, randomised multicentre trial

Rudolf Stadler Department of Dermatology, Academic Medical Centre, Minden, GermanyCorrespondence[email protected]
,
Thomas Luger University Medical School, Munster, Germany
,
Thomas Bieber University Medical School, Bonn, Germany
,
Ulrike Köhler University Medical School, Dresden, Germany
,
Ruthild Linse Department of Dermatology, Academic Medical Centre, Erfurt, Germany
,
Kristin Technau University Medical School, Freiburg, Germany
,
Roland Schubert University Medical School, Ulm, Germany
,
Katja Schroth Department of Dermatology, Municipal Hospital, Hildesheim, Germany
,
Feredoun Vakilzadeh Department of Dermatology, Municipal Hospital, Hildesheim, Germany
,
Matthias Volkenandt University Medical School, Munich, Germany
,
Harald Gollnick University Medical School, Magdeburg, Germany
,
Harald Von Eick , Laupheim, Germany
,
Fredrik Thoren Department of Clinical Virology, University of Göteborg, Sweden
&
Örjan Strannegård Department of Clinical Virology, University of Göteborg, Sweden
 show all
Pages 389-399 | Received 24 Feb 2005, Published online: 08 Jul 2009

Citations (28)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (3)

Örjan Strannegård & Fredrik B. Thorén. (2016) Opposing effects of immunotherapy in melanoma using multisubtype interferon-alpha – can tumor immune escape after immunotherapy accelerate disease progression?. OncoImmunology 5:3.
Read now
Ilkka O. Koskivuo, Ilpo A.J. Kinnunen, Erkki A. Suominen, Lauri A.I. Talve, Pia P. Vihinen & Reidar A. Grénman. (2009) Head and neck cutaneous melanoma: A retrospective observational study on 146 patients. Acta Oncologica 48:3, pages 460-467.
Read now
Johan Hansson. (2006) Adjuvant therapy of cutaneous melanoma – current status. Acta Oncologica 45:4, pages 369-372.
Read now

Articles from other publishers (25)

Kabirraaj Toor, Mark R. Middleton, Keith Chan, Adenike Amadi, Andriy Moshyk & Srividya Kotapati. (2021) Comparative efficacy and safety of adjuvant nivolumab versus other treatments in adults with resected melanoma: a systematic literature review and network meta-analysis. BMC Cancer 21:1.
Crossref
Tara D. Baetz, Glenn G. Fletcher, Gregory Knight, Elaine McWhirter, Sudha Rajagopal, Xinni Song & Teresa M. Petrella. (2020) Systemic adjuvant therapy for adult patients at high risk for recurrent melanoma: A systematic review. Cancer Treatment Reviews 87, pages 102032.
Crossref
Elaine Binkley, Pierre L Triozzi, Lisa Rybicki, Susan Achberger, Wayne Aldrich & Arun Singh. (2020) A prospective trial of adjuvant therapy for high-risk uveal melanoma: assessing 5-year survival outcomes. British Journal of Ophthalmology 104:4, pages 524-528.
Crossref
Jae-Hee Chung, Seon-Hui Hong, Nari Seo, Tae-Shin Kim, Hyun Joo An, Pedro Lee, Eui-Cheol Shin & Ho Min Kim. (2020) Structure-based glycoengineering of interferon lambda 4 enhances its productivity and anti-viral potency. Cytokine 125, pages 154833.
Crossref
Rohini Sharma, Roy Koruth, Steve Kanters, Eric Druyts & Ahmad Tarhini. (2019) Comparative efficacy and safety of dabrafenib in combination with trametinib versus competing adjuvant therapies for high-risk melanoma. Journal of Comparative Effectiveness Research 8:16, pages 1349-1363.
Crossref
Tyler Cassidy & Morgan Craig. (2019) Determinants of combination GM-CSF immunotherapy and oncolytic virotherapy success identified through in silico treatment personalization. PLOS Computational Biology 15:11, pages e1007495.
Crossref
Rakel Brendsdal Forthun, Monica Hellesøy, André Sulen, Reidun Kristin Kopperud, Gry Sjøholt, Øystein Bruserud, Emmet McCormack & Bjørn Tore Gjertsen. (2019) Modulation of phospho-proteins by interferon-alpha and valproic acid in acute myeloid leukemia. Journal of Cancer Research and Clinical Oncology 145:7, pages 1729-1749.
Crossref
Pierre L. Triozzi & Arun D. Singh. (2015) Adjuvant Therapy of Uveal Melanoma: Current Status. Ocular Oncology and Pathology 1:1, pages 54-62.
Crossref
Mauricio García, Sandra Díaz, Angélica Gutiérrez, Jesús Sánchez & Ricardo Sánchez. (2015) Experiencia clínica en el tratamiento adyuvante de los pacientes con melanoma de tronco y extremidades estado III en un hospital del Tercer Mundo. Revista Colombiana de Cancerología 19:1, pages 10-17.
Crossref
Fredrik B. Thorén, Harald Anderson & Örjan Strannegård. (2013) Late divergence of survival curves in cancer immunotherapy trials: interpretation and implications. Cancer Immunology, Immunotherapy 62:10, pages 1547-1551.
Crossref
Jazlyn Read. (2013) Recent advances in cutaneous melanoma: towards a molecular model and targeted treatment. Australasian Journal of Dermatology 54:3, pages 163-172.
Crossref
Pierre L Triozzi, Susan Achberger, Wayne Aldrich, Arun D Singh, Ronald Grane & Ernest C Borden. (2012) The association of blood angioregulatory microRNA levels with circulating endothelial cells and angiogenic proteins in patients receiving dacarbazine and interferon. Journal of Translational Medicine 10:1.
Crossref
J.M.G. Larkin, R.A. Fisher & M.E. Gore. (2012) Adjuvant Interferon Therapy for Patients at High Risk for Recurrent Melanoma: An Updated Systematic Review. Clinical Oncology 24:6, pages 410-412.
Crossref
T. Petrella, S. Verma, K. Spithoff, I. Quirt & D. McCready. (2012) Adjuvant Interferon Therapy for Patients at High Risk for Recurrent Melanoma: An Updated Systematic Review and Practice Guideline. Clinical Oncology 24:6, pages 413-423.
Crossref
Hedwig Stanisz, Thomas Vogt & Knuth Rass. 2012. Diagnostic and Prognostic Biomarkers and Therapeutic Targets in Melanoma. Diagnostic and Prognostic Biomarkers and Therapeutic Targets in Melanoma 247 263 .
Michelle Hong, Anne-Laure Puaux, Caleb Huang, Laure Loumagne, Charlene Tow, Charles Mackay, Masashi Kato, Armelle Prévost-Blondel, Marie-Françoise Avril, Alessandra Nardin & Jean-Pierre Abastado. (2011) Chemotherapy Induces Intratumoral Expression of Chemokines in Cutaneous Melanoma, Favoring T-cell Infiltration and Tumor Control. Cancer Research 71:22, pages 6997-7009.
Crossref
Fredrik B Thoren & Örjan Strannegård. (2011) Adjuvant interferon: extended follow-up times needed?. The Lancet Oncology 12:5, pages 419.
Crossref
K.C. Kähler, F. Egberts, A. Hauschild & P. Mohr. (2010) Adjuvante systemische Therapie des MelanomsAdjuvant systemic treatment of melanoma. Der Onkologe 16:12, pages 1150-1159.
Crossref
S. Mocellin, S. Pasquali, C. R. Rossi & D. Nitti. (2010) Interferon Alpha Adjuvant Therapy in Patients With High-Risk Melanoma: A Systematic Review and Meta-analysis. JNCI Journal of the National Cancer Institute 102:7, pages 493-501.
Crossref
Merlin Guggenheim, Pietro Giovanoli, Brigitta G. Baumert, Thomas Kurt Eigentler, Claus Garbe, Joanna Mangana & Reinhard Dummer. 2011. Skin Cancer - A World-Wide Perspective. Skin Cancer - A World-Wide Perspective 307 341 .
Tatsuya TAKENOUCHI & Akihito TAKAHASHI. (2009) Efficacy of postoperative adjuvant chemotherapy for malignant melanoma : a retrospective comparative study. Skin Cancer 24:2, pages 229-233.
Crossref
C. Garbe, P. Radny, R. Linse, R. Dummer, R. Gutzmer, J. Ulrich, R. Stadler, M. Weichenthal, T.K. Eigentler, U. Ellwanger & A. Hauschild. (2008) Adjuvant low-dose interferon α2a with or without dacarbazine compared with surgery alone: a prospective-randomized phase III DeCOG trial in melanoma patients with regional lymph node metastasis. Annals of Oncology 19:6, pages 1195-1201.
Crossref
Gaurav D. Shah & Paul B. Chapman. (2007) Adjuvant Therapy of Melanoma. The Cancer Journal 13:3, pages 217-222.
Crossref
A. Hauschild & C. Kähler. (2007) Adjuvante Interferontherapie beim Hochrisikomelanom. best practice onkologie 2:2, pages 4-13.
Crossref
A. Hauschild & U. R. Kleeberg. (2006) Adjuvante Therapie des MelanomsAdjuvant therapy of melanoma. Der Hautarzt 57:9, pages 764-772.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.